RISANKIZUMAB RZAA and COVID 19

2,211 reports of this reaction

2.4% of all RISANKIZUMAB RZAA reports

#7 most reported adverse reaction

Overview

COVID 19 is the #7 most commonly reported adverse reaction for RISANKIZUMAB RZAA, manufactured by AbbVie Inc.. There are 2,211 FDA adverse event reports linking RISANKIZUMAB RZAA to COVID 19. This represents approximately 2.4% of all 92,878 adverse event reports for this drug.

RISANKIZUMAB RZAA has an overall safety score of 78 out of 100. Patients taking RISANKIZUMAB RZAA who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COVID 192,211 of 92,878 reports

COVID 19 is a less commonly reported adverse event for RISANKIZUMAB RZAA, but still significant enough to appear in the safety profile.

Other Side Effects of RISANKIZUMAB RZAA

In addition to covid 19, the following adverse reactions have been reported for RISANKIZUMAB RZAA:

Other Drugs Associated with COVID 19

The following drugs have also been linked to covid 19 in FDA adverse event reports:

ACALABRUTINIBACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBRACETAMINOPHEN, DEXTROMETHORPHAN HBRACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATEACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCLACETAMINOPHEN, DEXTROMETHORPHAN HBR, GUAIFENESIN, PHENYLEPHRINE HCLACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCLACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDEACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATEACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDEACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATEACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDEACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDEACETAMINOPHEN, PHENYLEPHRINE HCLADRENALINUMAGNUS CASTUSAPIXABANATOGEPANTAVOBENZONE, HOMOSALATE, OCTOCRYLENEAZELASTINE

Frequently Asked Questions

Does RISANKIZUMAB RZAA cause COVID 19?

COVID 19 has been reported as an adverse event in 2,211 FDA reports for RISANKIZUMAB RZAA. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COVID 19 with RISANKIZUMAB RZAA?

COVID 19 accounts for approximately 2.4% of all adverse event reports for RISANKIZUMAB RZAA, making it a notable side effect.

What should I do if I experience COVID 19 while taking RISANKIZUMAB RZAA?

If you experience covid 19 while taking RISANKIZUMAB RZAA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages

RISANKIZUMAB RZAA Full ProfileAll Drugs Causing COVID 19AbbVie Inc. Drugs
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.